Enprofylline - Effects of a New Bronchodilating Xanthine Derivative in Asthmatic Patients
- 1 January 1983
- Vol. 38 (1) , 75-79
- https://doi.org/10.1111/j.1398-9995.1983.tb00859.x
Abstract
The bronchodilating effect of two doses of peroral enproffylline was compared with Placebo in 24 asthmatic patients, Enprofylline produced significantly greater bronchodilatation than placebo, A dose of 2 mg/kg b.wt. and 4 mg/kg b.wt. caused a mean maximal increase in FEV1 of 26% and 35%, respectively. The degree and the incidence of headache and nausea were estimated by means of a scoring system. Dose-related effects on both parameters observed. Other side effects were negligible. In seven patients the means plasma half-life of enprofylline was found to be 113 min. It is suggested that enprofylline should be studied further in Patients suffering from obstructive lung disease.Keywords
This publication has 5 references indexed in Scilit:
- Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung diseaseEuropean Journal of Clinical Pharmacology, 1982
- Enprofylline, a Principally New Antiasthmatic XanthineActa Pharmacologica et Toxicologica, 1981
- Adenosine receptors in the central nervous system: Relationship to the central actions of methylxanthinesLife Sciences, 1981
- Renal effects of adenosine and their inhibition by theophylline in dogsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1975